← All companies ← ANGX Manual ANSS → ← ANAB Pharmaceuticals AQST →
ANIP, ANI Pharmaceuticals Inc.
ANI Pharmaceuticals is a diversified bio-pharmaceutical company.
The Company's mission is "Serving Patients, Improving Lives" by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses.
In connection with the acquisition, the Company added two new products, ILUVIEN ("ILUVIEN") and YUTIQ ("YUTIQ").
The business
What it sells, where the money comes from, the kind of company it is.
The business in brief
read the 10-K →What this business is and what moves its needle, from its own SEC filings.
- Situation
- Cyclical. Margins collapse and recover repeatedly across the record; a single year, good or bad, misstates the through-cycle earning power.
- What moves the needle
- Gross margin has run about 62% and operating margin about 7.9% through the cycle, a wide spread between price and the cost of what it sells — whether that advantage is durable pricing power or a margin that can erode is the question the record is for. The operating margin has swung widely — from −18% to 18% — on a steadier 62% gross margin, so what moves it sits below the gross line, in operating spend and one-off charges more than in the cost of the product itself. Inventory runs near 22% of sales, so how fast it turns back into cash — and the risk of writing it down when demand softens — sits alongside the margin. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on customer concentration, set against the numbers in what the filing emphasizes, below.
- Is it a good business?
- Return on capital has rarely cleared the cost of capital (median 4%, above 15% in 1 of 10 years). By owner earnings: roughly 17% of revenue reaches owners as cash, consistently. The cycle and the balance sheet decide this one; the worst year tells more than the median, and the rest is in the 10-K.
Every line is arithmetic on the company's filings, shown in full in the sections below.
The record
Ten years of arithmetic, read across the cycle.
The record, 2016–2025
realized figures from each filing · older years to the left| 2016’16 | 2017’17 | 2018’18 | 2019’19 | 2020’20 | 2021’21 | 2022’22 | 2023’23 | 2024’24 | 2025’25 | TTMTTMMar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| $129M | $177M | $202M | $207M | $208M | $216M | $316M | $487M | $614M | $883M | $924M | RevenueRevenue |
| 62% | 55% | 64% | 69% | 58% | — | — | — | — | — | 91% | Gross marginGross mgn |
| 22% | 18% | 22% | 27% | 31% | 39% | 39% | 33% | 41% | 36% | 34% | SG&A / revenueSG&A/rev |
| 2% | 5% | 8% | 10% | 8% | 5% | 7% | 7% | 7% | 6% | 6% | R&D / revenueR&D/rev |
| $20M | $28M | $35M | $16M | ($16M) | ($40M) | ($35M) | $47M | $584K | $111M | $124M | Operating incomeOp. inc. |
| 15.6% | 16.0% | 17.5% | 7.9% | −7.7% | −18.4% | −11.2% | 9.6% | 0.1% | 12.6% | 13.4% | Operating marginOp. mgn |
| $4M | ($1M) | $15M | $6M | ($23M) | ($43M) | ($48M) | $19M | ($19M) | $78M | $92M | Net incomeNet inc. |
| 55% | — | 23% | — | — | — | — | 6% | — | 18% | 21% | Effective tax rateTax rate |
| Cash flow & returns | |||||||||||
| $27M | $39M | $67M | $46M | $15M | $3M | ($31M) | $119M | $64M | $185M | $209M | Operating cash flowOp. cash |
| $22M | $28M | $34M | $45M | $45M | $47M | $57M | $60M | $68M | $91M | $89M | DepreciationDeprec. |
| ($5M) | $6M | $11M | ($14M) | ($20M) | ($12M) | ($55M) | $20M | ($15M) | ($22M) | ($12M) | Working capital & otherWC & other |
| $5M | $10M | $6M | $7M | $6M | $3M | $9M | $9M | $16M | $14M | $17M | CapexCapex |
| 3.5% | 5.9% | 2.8% | 3.2% | 2.9% | 1.2% | 2.8% | 1.8% | 2.6% | 1.6% | 1.9% | Capex / revenueCapex/rev |
| $23M | $29M | $61M | $39M | $9M | $765K | ($40M) | $110M | $48M | $171M | $191M | Owner earningsOwner earn. |
| 17.8% | 16.4% | 30.4% | 18.9% | 4.4% | 0.4% | −12.7% | 22.6% | 7.8% | 19.4% | 20.7% | Owner earnings marginOE mgn |
| $23M | $29M | $61M | $39M | $9M | $765K | ($40M) | $110M | $48M | $171M | $191M | Free cash flowFCF |
| 17.8% | 16.4% | 30.4% | 18.9% | 4.4% | 0.4% | −12.7% | 22.6% | 7.8% | 19.4% | 20.7% | Free cash flow marginFCF mgn |
| $0 | $0 | $16M | $0 | $0 | $84M | $33K | $0 | — | — | $0 | AcquisitionsAcquis. |
| — | — | — | $0 | $0 | $190K | $2M | $2M | $2M | $1M | $751K | Dividends paidDiv. paid |
| $3M | $0 | $0 | $1M | $2M | $890K | $2M | $5M | $11M | $12M | — | BuybacksBuybacks |
| 4% | 5% | 12% | 5% | -3% | -6% | -5% | 9% | 0% | 16% | 18% | ROICROIC |
| 2% | -1% | 8% | 3% | -12% | -13% | -15% | 4% | -5% | 14% | 16% | Return on equityROE |
| — | — | — | 3% | −12% | −13% | −16% | 4% | −5% | 14% | 16% | Retained to equityRetained/eq |
| Balance sheet | |||||||||||
| $27M | $31M | $43M | $62M | $8M | $100M | $48M | $221M | $145M | $286M | $311M | Cash & investmentsCash+inv |
| $46M | $59M | $65M | $72M | $96M | $129M | $165M | $162M | $222M | $281M | $255M | ReceivablesReceiv. |
| $26M | $38M | $41M | $48M | $61M | $82M | $105M | $111M | $137M | $143M | $143M | InventoryInvent. |
| $3M | $4M | $9M | $15M | $11M | $23M | $29M | $37M | $46M | $63M | $70M | Accounts payablePayables |
| $69M | $93M | $96M | $106M | $145M | $187M | $241M | $237M | $313M | $362M | $329M | Operating working capitalOper. WC |
| $103M | $132M | $153M | $188M | $170M | $322M | $344M | $520M | $528M | $753M | $747M | Current assetsCur. assets |
| $32M | $39M | $166M | $62M | $79M | $88M | $99M | $145M | $194M | $278M | $240M | Current liabilitiesCur. liab. |
| 3.2× | 3.4× | 0.9× | 3.0× | 2.2× | 3.7× | 3.5× | 3.6× | 2.7× | 2.7× | 3.1× | Current ratioCurr. ratio |
| $2M | $2M | $4M | $4M | $4M | $28M | $28M | $28M | $60M | $62M | $62M | GoodwillGoodwill |
| $323M | $412M | $431M | $457M | $461M | $772M | $760M | $904M | $1.3B | $1.4B | $1.4B | Total assetsAssets |
| $121M | $128M | $71M | $186M | $186M | $287M | $287M | $286M | $318M | $309M | $305M | Total debtDebt |
| $93M | $97M | $28M | $123M | $178M | $187M | $238M | $65M | $173M | $24M | ($6M) | Net debt / (cash)Net debt |
| $170M | $175M | $197M | $213M | $196M | $334M | $314M | $433M | $404M | $541M | $562M | Shareholders’ equityEquity |
| 4.7% | 3.4% | 3.4% | 4.5% | 6.2% | 4.9% | 4.6% | 4.2% | 4.8% | 4.3% | 4.2% | Stock comp / revenueSBC/rev |
| Per share | |||||||||||
| 11.6M | 11.5M | 11.8M | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.3M | 21.2M | 21.5M | Shares out (diluted)Shares |
| $11.11 | $15.31 | $17.12 | $17.16 | $17.43 | $17.16 | $19.46 | $26.76 | $31.80 | $41.61 | $42.88 | Revenue / shareRev/sh |
| $0.34 | $-0.09 | $1.32 | $0.51 | $-1.88 | $-3.38 | $-2.95 | $1.03 | $-0.96 | $3.69 | $4.28 | EPS (diluted)EPS |
| $1.98 | $2.52 | $5.21 | $3.24 | $0.76 | $0.06 | $-2.46 | $6.05 | $2.47 | $8.07 | $8.87 | Owner earnings / shareOE/sh |
| $1.98 | $2.52 | $5.21 | $3.24 | $0.76 | $0.06 | $-2.46 | $6.05 | $2.47 | $8.07 | $8.87 | Free cash flow / shareFCF/sh |
| — | — | — | $0.00 | $0.00 | $0.02 | $0.10 | $0.09 | $0.08 | $0.05 | $0.03 | Dividends / shareDiv/sh |
| $0.39 | $0.90 | $0.49 | $0.55 | $0.51 | $0.20 | $0.55 | $0.49 | $0.84 | $0.65 | $0.81 | Cap. spending / shareCapex/sh |
| $14.66 | $15.13 | $16.76 | $17.67 | $16.36 | $26.51 | $19.29 | $23.79 | $20.90 | $25.47 | $26.10 | Book value / shareBVPS |
| 9-yr | 5-yr | |
|---|---|---|
| Revenue / share | +15.8%/yr | +19.0%/yr |
| Owner earnings / share | +16.9%/yr | +60.3%/yr |
| EPS | +30.3%/yr | — |
| Capital spending / share | +5.7%/yr | +4.9%/yr |
| Book value / share | +6.3%/yr | +9.3%/yr |
The record, charted
FY2016–2025Each measure over its full record; the current point and the worst year marked.
Owner earnings vs. net income
Owner earningsNet incomeThe accountant's number, and the cash an owner can take; the gap is the tell.
Where the cash went
ReinvestBuybacksDividendsAcquisitionsRetainedBeyond op. cashEach year's outlays against its operating cash: the mix, and how it drifts. The hatched cap is spending beyond that year's operating cash — financed from the balance sheet or borrowing, not operations.
Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.
In fiscal 2025 the business turned $78M of profit into $171M of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Reported net income | $78M | ($19M) | $19M | ($48M) | ($43M) |
| Depreciation & amortizationnon-cash charge added back | +$91M | +$68M | +$60M | +$57M | +$47M |
| Stock-based compensationreal costnon-cash, but a real cost | +$38M | +$29M | +$21M | +$15M | +$10M |
| Working capital & othertiming of cash in and out, other non-cash items | −$22M | −$15M | +$20M | −$55M | −$12M |
| Cash from operations | $185M | $64M | $119M | ($31M) | $3M |
| Capital expenditurecash put back in to keep running and to grow | −$14M | −$16M | −$9M | −$9M | −$3M |
| Owner earnings | $171M | $48M | $110M | ($40M) | $765K |
| Owner-earnings marginowner earnings ÷ revenue | 19% | 8% | 23% | -13% | 0% |
Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $38M), owner earnings is nearer $133M.
Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.
Quality & stewardship
Returns, the balance sheet, capital allocation, and pay.
Owner’s Scorecard
Will it survive?
- Can it pay its interest? 237.9×ComfortableOperating income $111M ÷ interest expense $467K
What this means
Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.
- How heavy is the debt, net of cash? $24M · 0.2× operating profitModest net debtCash $286M − debt $309M
What this means
Netting $286M of cash and short-term investments against $309M of debt leaves $24M owed, about 0.2× a year's operating profit (2.8× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.
- Long (60+ days)DSO 116 + DIO 599 − DPO 262 days
What this means
Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.
Is it a good business?
- Below average through the cycle10-yr median, range -6%–16%; 16% latest = NOPAT $91M ÷ invested capital $564MIndustry peers: median 6%
What this means
The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 16% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.
- High through the cycle10-yr median margin, range -13%–30%; latest $171M = operating cash $185M − maintenance capex $14MIndustry peers: median 8%
What this means
What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 19% of revenue this year, a 16% median across 10 years. Treating stock comp as the real expense it is (less $38M of SBC) leaves $133M.
- Cash-backedCash from ops $185M ÷ net income $78M
What this means
How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.
How is the cash used?
- Reinvests most of itDividends + buybacks $13M ÷ Owner Earnings $171M
What this means
Of $171M Owner Earnings, $13M (8%) went back to shareholders, $1M dividends, $12M buybacks. But the buybacks barely exceed stock issued to employees ($38M SBC), net of dilution, little was truly returned. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.
- Investing or harvesting? 0.15×HarvestingCapex $14M ÷ depreciation $91M
What this means
Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.
Graham’s defensive tests · 3 of 6 met
Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.
- Adequate size MissRevenue ≥ $2B · $883M
What this means
Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.
- Strong liquidity PassCurrent ratio ≥ 2× · 2.71×
What this means
Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.
- Conservative debt PassDebt ≤ working capital · $309M vs $475M WC
What this means
Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.
- Earnings stability MissA profit every year (10-yr record) · 5 loss years
What this means
Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.
- Dividend record MissUninterrupted dividends · 5 of 10 yrs
What this means
An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.
- Earnings growth PassEarnings +33% over the record · +328%
What this means
At least a third more earnings than a decade ago, averaging three years at each end. Net income (not per-share), so stock splits don't distort it, buybacks and dilution show up in the share-count line instead.
- Moderate price —P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
What this means
Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $1.16/share (latest year $3.48), the averaged base the calculator's gate runs on, and book value is $24.04/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.
Durability & moat, 2016–2025
Whether the record’s returns held, and what the capital reinvested earned.
- Profitable years 5 of 10
What this means
Lost money in 5 year(s), look at what happened there before trusting the average.
- Return on capital ≥ 15% 1 of 10 yrs
What this means
A moat shows up as a high return on invested capital that holds year after year, not one good vintage.
- Operating margin 16% → 7% (3-yr avg ends)
What this means
Through the cycle the operating margin slipped — about 16% early to 7% lately, median 8% — competition or costs are biting in.
- Reinvestment, incremental ROIC 10%
What this means
Reinvested capital came back at only a modest incremental return — near the cost of capital, where extra growth adds little per dollar. The record shows whether it is a soft stretch or a thinning moat.
- Owner earnings growth +17%/yr
What this means
Owner earnings grew about 17% a year over the record.
- Worst year 2021 · −18.4% op. margin
What this means
Operations went underwater in 2021, understand why before trusting the good years.
- Dividend record rising
What this means
Paid and raised the dividend across the record, the continuity Graham prized.
Does AI threaten the moat?
Low contestabilityThe moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.
Its FY2025 10-K names artificial intelligence as a competitive threat, in language that was not in the prior year's filing.
“We may also face increased competition from other companies that are using AI, some of which may develop more effective methods to deploy these technologies than we or any of our business partners have, which could impair our ability to compete effectively.”
AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.
Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.
All figures as filed; the source filing is linked above.
Current Position
as of the latest quarter, Mar 31, 2026Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.
- Cash & short-term investments$311M
- Receivables$255M
- Inventory$143M
- Other current assets$37M
- Debt due within a year$19M
- Accounts payable$70M
- Other current liabilities$151M
From the company's latest filing.
How the cash was used, 2016–2025
Over the record, the business generated $535M of operating cash; how management split it reads as a cash builder, a large share of cash simply built up on the balance sheet.
- Reinvested$84M · 16%
- Dividends$6M · 1%
- Buybacks$36M · 7%
- Retained (debt / cash)$409M · 76%
- Returned to owners$42M
9% of the owner earnings the business produced over the span, $6M as dividends and $36M as buybacks.
- Source of fundingOperating cash
Operating cash covered reinvestment and returns; over the span debt rose $185M and cash and short-term investments rose $284M.
- Average price paid for buybacks—
Buybacks ran $36M over the span, but the filings don't tag the share count needed to deduce the average price paid.
- Net change in share count86.2%
The diluted count rose from 12M to 22M: issuance (stock pay, deals) outran any buybacks, so owners were diluted on net.
- Dividend record$0.05/sh
Paid in 5 of the years on record. It was cut at least once along the way.
Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.
Acquisitions & goodwill
from the balance sheet & the 10-year cash-flow recordGoodwill grows only when a company acquires and falls only when it concedes it overpaid. The size of that bet, the cash put into buying rather than building, and how much has already been written off.
None written down over the record; the goodwill is still carried at full cost. That is the deals holding their value on the books so far; whether they keep doing so is the test an owner watches, since the write-down, when it comes, is the admission the price was too high.
Goodwill, acquired intangibles and equity from the latest balance sheet; acquisition spend and write-downs summed across the 10-year record, from the company's own filings.
Management, ownership & pay
read the proxy →From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.
| Fiscal year | Chief executive | Pay, as filed | “Actually paid” | Owner earnings |
|---|---|---|---|---|
| 2021 | Nikhil Lalwani | $6.5M | $10.5M | $765K |
| 2022 | Nikhil Lalwani | $5.1M | $4.6M | ($40M) |
| 2023 | Nikhil Lalwani | $8.1M | $15.1M | $110M |
| 2024 | Nikhil Lalwani | $8.9M | $10.8M | $48M |
| 2025 | Nikhil Lalwani | $10.3M | $21.3M | $171M |
Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.
- Insider ownership8.1%
The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.
- Stock-based compensation$38M
The slice of the business handed to employees in shares this year, 4% of revenue, equal to 34% of operating profit. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.
Inverting the record
Invert: instead of why ANI Pharmaceuticals Inc. is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2016–2025.
2 of the 5 tests turned up something to look into; the other 3 came back clean.
- Look hereDid the share count rise anyway?86.2%
Diluted shares grew 86.2% over 2016–2025, even as the company spent $36M on buybacks. The repurchases were outrun by issuance — to staff, in a raise, or in a deal — and the filing says which; owners' slice still shrank. Read the buyback line beside this one, not on its own.
- Look hereAre "one-time" charges a yearly habit?8 of 10 years
Management took an impairment or write-down in 8 of the last 10 years, $19M in all. A charge taken almost every year is not one-time; it is the business — past deals coming due, and an admission the assets were worth less than what was paid. Munger's rule: when the "one-time" keeps happening, it is the business. Read it beside the goodwill the company still carries.
- Is it less profitable than it was?
- Did debt outgrow the business?
- Did receivables and inventory outpace sales?
Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.
What an owner would ask, FY2025
read the 10-K →- How much of the revenue rides on one buyer?≈$490M · 53% of revenue on the largest customers (TTM)
“For the year ended December 31, 2025, approximately 53% of our net revenues were attributable to three customers.”verify →
- Which reported numbers are a judgment call?Management names Revenue recognition, Income taxes, Acquisitions, Stock compensation as critical estimates
each rests partly on management's judgment; the filing's note sets out the assumptionsverify →
The questions the record and the charts do not answer on their own; each carries the figure and the place to look.
Peers, Pharmaceuticals
The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.
| Company | Revenue | Gross margin | Op. margin | ROIC | Owner earn. margin |
|---|---|---|---|---|---|
| MDGLMadrigal Pharmaceuticals Inc. | $958M | 99% | -276.4% | -61% | -254% |
| IONSIonis Pharmaceuticals | $944M | 99% | -16.9% | -11% | -14% |
| ANIPANI Pharmaceuticals Inc. | $883M | 62% | 8.8% | 4% | 17% |
| HRMYHarmony Biosciences Holdings Inc. | $868M | 79% | 26.7% | 38% | 32% |
| ARWRArrowhead Pharmaceuticals | $829M | — | -106.8% | -51% | -77% |
| COLLCollegium Pharmaceutical Inc. | $781M | 56% | 6.8% | 44% | 31% |
| CORTCorcept Therapeutics Incorporated | $761M | 98% | 30.6% | 25% | 34% |
| EBSEmergent BioSolutions Inc. | $743M | 58% | 12.5% | 6% | 8% |
| Group median | — | 79% | 7.8% | 5% | 13% |
The price
What a price has to assume.
What the price implies
reverse-DCFType today's close and see the owner-earnings growth you'd have to believe to justify it, beside what ANI Pharmaceuticals Inc. has delivered.
Through the cycle, ANI Pharmaceuticals Inc. earns about $151M on its 17.1% median owner-earnings margin. This year’s 19.4% margin runs in line with that. Normalize, below, values the price on that through-cycle figure rather than the latest year.
—
9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.
Enter a price above to run it.
A dated snapshot of the price you typed, the assumptions you set, and what the page showed for them. A snapshot is never edited after it is saved. Your notebook is yours alone — the commitment states what is stored and what we will never do.
Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.
Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.
Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.
Free cash flow $191M on 22M shares outstanding, the balance-sheet count at 2025-12-31; net cash $6M. The base is the latest year by default; Normalize values it on the through-cycle median owner-earnings margin (to avoid paying on a peak year). Net of stock comp treats option pay as the expense it is. Capex ($17M) runs well above depreciation ($89M), so this is a build-out; Steady-state swaps total capex for maintenance (≈ depreciation), lifting the base to about $195M, the cash it would throw off if it stopped expanding. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.
Manual order: ← ANGX its page in the Manual ANSS →
Industry order: ← ANAB the Pharmaceuticals chapter AQST →